Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)

被引:83
|
作者
Kevadiya, Bhavesh D. [1 ,4 ]
Patel, Tapan A. [2 ]
Jhala, Devendrasinh D. [2 ]
Thumbar, Rahul P. [3 ]
Brahmbhatt, Harshad [1 ]
Pandya, Maharshi P. [4 ]
Rajkumar, Shalini [4 ]
Jena, Prasant K. [4 ]
Joshi, Ghanshyam V. [1 ]
Gadhia, Pankaj K. [3 ]
Tripathi, C. B. [5 ]
Bajaj, Hari C. [1 ]
机构
[1] CSIR, Discipline Inorgan Mat & Catalysis, Cent Salt & Marine Chem Res Inst, Bhavnagar 364021, Gujarat, India
[2] Gujarat Univ, Dept Zool, Univ Sch Sci, Ahmadabad, Gujarat, India
[3] Veer Narmad S Gujarat Univ, Dept Biosci, Surat, Gujarat, India
[4] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India
[5] Govt Med Coll, Dept Pharmacol, Bhavnagar, Gujarat, India
关键词
Nanocomposites; Intercalation; Na+-clay; Controlled drug release; Genotoxicity; ADVANCED COLORECTAL-CANCER; DNA-DAMAGE; RELEASE; FLUOROURACIL; DELIVERY; THERAPY; MONTMORILLONITE; NANOPARTICLES; MECHANISMS;
D O I
10.1016/j.ejpb.2012.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here the intercalation of 5-fluorouracil (5-FU), an anticancer drug in interlayer gallery of Na+ clay (Montmorillonite, MMT), with the assistance of biopolymer (chitosan, CS). The X-ray diffraction patterns, thermal and spectroscopic analyses indicated the drug intercalation into the clay interlayer space in support of CS and stabilized in the longitudinal monolayer by electrostatic interaction. In vitro drug release showed controlled release pattern. The genotoxic effect of drug was in vitro evaluated in human lymphocyte cell culture by comet assay, and results indicated significant reduction in DNA damage when drug was intercalated with clay and formulated in composites. The results of in vitro cell viability assay in cancer cells pointed at decreased toxicity of drug when encapsulated in Na+-clay plates than the pristine drug. In vivo pharmacokinetics, biodistribution, hepatotoxicity markers, e.g., SGPT and SGOT, and liver/testicular histology in rats showed plasma/tissue drug levels were within therapeutic window as compared to pristine drug. Therefore, drug-clay hybrid and composites can be of considerable value in chemotherapy of cancer with reduced side effects. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [31] TREATMENT OF KERATOACANTHOMAS BY LOCAL APPLICATIONS OF 5-FLUOROURACIL (5-FU) OINTMENT
    GRUPPER, C
    DERMATOLOGICA, 1970, 140 : 127 - &
  • [32] ORAL 5-FLUOROURACIL (5-FU) AS AN ADJUVANT TO SURGERY IN CARCINOMA OF COLON
    HARVEY, H
    BADDER, E
    DEMUTH, W
    NAHRWOLD, D
    PATTERSON, L
    RICCI, J
    SHAVER, W
    WHITE, D
    LIPTON, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 314 - 314
  • [33] EFFECTS OF 5-FLUOROURACIL (5-FU) OINTMENT IN TREATMENT OF NEOPLASTIC DERMATOSES
    KLEIN, E
    STOLL, HL
    MILLER, E
    MILGROM, H
    HELM, F
    BURGESS, G
    DERMATOLOGICA, 1970, 140 : 21 - +
  • [34] 5-FLUOROURACIL (5-FU) IN PRIMARY TRABECULECTOMY - A PROSPECTIVE, RANDOMIZED STUDY
    GOLDENFELD, M
    WONG, P
    RUDERMAN, J
    ROSENBERG, L
    KRUPIN, T
    GEISER, D
    LIEBMANN, J
    RITCH, R
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 815 - 815
  • [35] Continuous infusion of 5-fluorouracil (5-FU) in neuroendocrine tumours (NET)
    Ducreux, M
    Baudin, E
    Thabut, D
    Rougier, P
    Tigaud, JM
    Elias, D
    Boige, V
    Schlumberger, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S213 - S213
  • [36] CAN NMR CONTRIBUTE TO THE RADIOPHARMACOKINETICS OF 5-FLUOROURACIL (5-FU) IN MAN
    WOLF, W
    GRIFFITHS, JR
    SILVER, M
    BRUCKNER, H
    JOURNAL OF NUCLEAR MEDICINE, 1986, 27 (05) : 737 - 737
  • [37] A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
    Naik, Shailendra S.
    Vanidassane, Ilavarasi
    Dhamija, Ekta
    Sharma, Atul
    INDIAN JOURNAL OF RADIOLOGY AND IMAGING, 2020, 30 (02): : 214 - 217
  • [38] BIOCHEMICAL MODULATION OF 5-FLUOROURACIL (5-FU) ACTIVITY BY URIDINE (URD)
    VANGROENINGEN, CJ
    LEYVA, A
    PETERS, GJ
    LAURENSSE, E
    PINEDO, HM
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 132 - 132
  • [39] 5-FLUOROURACIL (5-FU) PHARMACOKINETICS FOLLOWING VARIOUS ROUTES OF ADMINISTRATION
    SADEE, W
    FINN, C
    SCHWANDT, HJ
    YALE, L
    LEE, YT
    BATEMAN, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 187 - 187
  • [40] 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy
    Legand, C.
    Blasco, H.
    Benz, I.
    Chapet, C.
    Le Guellec, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 25 - 25